1094 related articles for article (PubMed ID: 29736744)
1. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
3. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
6. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
7. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
8. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
9. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
10. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K
Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
[TBL] [Abstract][Full Text] [Related]
11. Ketamine for depression clinical issues.
Iqbal SZ; Mathew SJ
Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
[TBL] [Abstract][Full Text] [Related]
12. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
13. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.
Monteggia LM; Gideons E; Kavalali ET
Biol Psychiatry; 2013 Jun; 73(12):1199-203. PubMed ID: 23062356
[TBL] [Abstract][Full Text] [Related]
14. Ketamine: A tale of two enantiomers.
Jelen LA; Young AH; Stone JM
J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
[TBL] [Abstract][Full Text] [Related]
15. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
16. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
18. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Chang L; Zhang K; Pu Y; Qu Y; Wang SM; Xiong Z; Ren Q; Dong C; Fujita Y; Hashimoto K
Pharmacol Biochem Behav; 2019 Jun; 181():53-59. PubMed ID: 31034852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]